Q-omics provides the consensus-scored ZBTB20-AS3 profile across patient tissues and cancer cell-line models. ZBTB20-AS3 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB20-AS3 is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, ZBTB20-AS3 RNA expression shows 14,625 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, CHOL, and LUAD as cancer lineages where ZBTB20-AS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB20-AS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB20-AS3 survival associations across molecular data types. ZBTB20-AS3 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB20-AS3 RNA expression–survival associations across cancer types. High ZBTB20-AS3 expression shows unfavorable associations in KIRC, KIRP, CHOL, LUSC and UCEC, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB20-AS3 RNA expression.
This table summarizes ZBTB20-AS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB20-AS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB20-AS3 shows lower tumor expression in CHOL, KIRP and LUSC. The CHOL box plot shows higher ZBTB20-AS3 RNA expression in normal versus tumor tissue (log2 FC = −0.156, t-test p = .001).
This table shows molecular features associated with ZBTB20-AS3 in patient tissues and cancer cell lines. In patient samples, ZBTB20-AS3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
